Traders Recap: Melco Crown Entertainment Ltd (ADR)(NASDAQ:MPEL), Medtronic PLC (NYSE:MDT), Novartis AG (ADR)(NYSE:NVS)

On Friday, Shares of Melco Crown Entertainment Ltd (ADR)(NASDAQ:MPEL), subtract -1.52% and closed at $15.52 in the last trading session. The last trading range of the stock ranges between $15.33 and $16.16. City of Dreams Manila receives another accolade, affirming the luxury integrated resort’s service and product excellence that continues to draw acclaim from local and international visitors as a world-class leisure and entertainment destination.

Crown Towers Manila, one of three premier luxury hotels built at the 6.2 hectare complex, garnered two design awards in the prestigious International Hotel and Property Awards 2016, Best Hotel over 200 Rooms (Asia Pacific) and Best Lobby/Public Area/Lounge (Global), at an awards ceremony held recently at Hotel Cipriani in Venice.

“City of Dreams Manila carries the very best DNA of the Melco Crown Entertainment brand. Following Mr. Lawrence Ho, our Chairman and CEO’s grand vision, City of Dreams Manila has joined its sister properties in Macau to become the best in its breed,” Geoff Andres, Property President of City of Dreams Manila, remarked. “We are elated and proud over this international distinction that strengthens City of Dreams Manila’s position as the ultimate in entertainment and hospitality, offering a spectacular and cosmopolitan collection of contemporary and leisure experiences. It affirms our commitment to deliver outstanding quality products and services and enhance the leisure landscape in the country at a level equal to the best in the world.”

Medtronic PLC (NYSE:MDT), dropped -0.72% and closed at $82.71 in the last trading session. The last trading range of the stock ranges between $82.70 and $83.78. The company’s Market capitalization is $114.30 Billion with the total outstanding Shares of 1.38 billion. Medtronic plc (MDT) recently declared that it has notified customers of a voluntary recall of certain lots of its Pipeline(TM) embolization device, Alligator(TM) retrieval device and X-Celerator(TM) hydrophilic guidewire. The recall also includes the stylet containing UltraFlow(TM) flow directed micro catheters and Marathon(TM) flow directed micro catheters. These products are produced, marketed and sold by Medtronic`s Neurovascular business, which is part of the Brain Therapies division in the company`s Restorative Therapies Group.

This voluntary recall is being conducted because of the potential separation and detachment of the polytetrafluoroethylene (PTFE) coating on parts of these devices. Should the PTFE separate from the delivery wire or stylets, PTFE particulate could enter the blood stream of the patient. PTFE in the blood stream, based on the size and quantity, could lead to a thromboembolic event.

Medtronic initiated customer communication of the recall by letter on October 5, 2016, and is requesting customers to quarantine all affected product that remain in the inventory and return to Medtronic. The U.S. Food and Drug Administration (FDA) and other regulatory bodies also have been notified.

Novartis AG (ADR)(NYSE:NVS), lost -0.87% and closed at $76.09 in the last trading session. The last trading range of the stock ranges between $76.09 and $77.09. The company’s Market capitalization is $199.18 Billion with the total outstanding Shares of 2.38 billion. During the 52-week trading session the minimum price at which share price traded, registered at $69.89 and reached to max level of $95.11. Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, counting ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates mainly antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, in addition to biotechnology manufacturing services to other companies.

Leave a Reply

Your email address will not be published. Required fields are marked *